EGFR and neoplasm: With binding to Cetuximab (Erbitux), a 152 kDa recombinant monoclonal antibody combined with the extracellular domain of EGFR, H2a-4T@Cetuximab complex could exhibit a remarkable cell-killing ability and achieve highly selective tumor-targeting ability in vivo, showing that H2a-4T@Cetuximab complex was potential for tumor theranostics.